Changes to US and China Tariffs Have No Impact on TruScreen

NZX/ASX Announcement
7/04/2025
Changes to US and China Tariff Regimes have no impact on TruScreen
• TruScreen’s unique AI enabled cervical cancer screening device is not impacted by changes
to the US and China proposed tariff regimes
• Focus on emerging markets ensures TruScreen sales are unaffected by increased tariffs on
Australian products entering the USA
• TruScreen markets both an Australian and a Made in China device providing a dual product
strategy in the key China market, with preferential market access for China manufactured
products
• China proposed retaliatory 34% tariff on US made products entering China strengthen
TruScreen’s domestic manufactured advantage
TruScreen Group Limited (“TruScreen” or “the Company”) advises that its unique AI enabled
cervical cancer screening device is not impacted by changes to the US and China proposed tariff
regimes.
TruScreen has pursued an emerging markets strategy. The United States is currently not a
distribution territory or strategic focus for TruScreen.
The TruScreen device is a particularly appropriate primary cervical cancer screening tool in regions
with high mortality to cervical cancer. TruScreen’s growth strategy focuses on emerging markets,
especially China, and Low and Middle Income Countries (LMICs) such as India, Indonesia, Mexico,
Vietnam, Uzbekistan and Zimbabwe.
TruScreen manufactures both an Australian and a Chinese made device. This strategy de-risks
government policy changes in the key China market, where there is a preferential purchasing policy
for China manufactured products.
The announcement that China proposes to impose a retaliatory 34% tariff on US made products into
China will strengthen TruScreen’s Made in China competitive advantage over imported US
manufactured cytology (pap smear) and HPV DNA products.

This announcement has been approved by the Board.
Ends
For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
martindillon@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines,
among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing
facility in China for devices marketed and sold in China. TruScreen currently does not distribute its
medical device in the USA.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To
date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and
Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a
special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the
cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can
be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked
to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test
may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council